3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
20
Phase 2
2
Phase 4
1
Phase 3
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Melanoma
3
Breast Neoplasms
2
Thymic aplasia
1
Small Cell Lung Carcinoma
1
Pain, Postoperative
1
Neoplasms
1
Lung Neoplasms
1
Immunologic Deficiency Syndromes
1
Hematologic Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Pemetrexed
10
Cisplatin
9
Erlotinib Hydrochloride
8
Carboplatin
7
icotinib
5
Gefitinib
5
Docetaxel
5
endostar protein
3
Zoledronic Acid
3
Radiotherapy
3
Paclitaxel
3
Gemcitabine
3
Endostatins
3
Afatinib
3
tislelizumab
2
pembrolizumab
2
osimertinib
2
lorlatinib
2
flurbiprofen axetil
2
dexamethasone 21-phosphate
2
atezolizumab
2
Vinorelbine
2
Surgical Procedures, Operative
2
Saline Solution
2
Nivolumab
2
Drug Therapy
2
Dexamethasone
2
Chemoradiotherapy
2
trametinib
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Carcinoma, Non-Small-Cell Lung
×
Blood Specimen Collection
×
Clear all
NCT04180176
2024-01-17
PCG
Genentech, Inc.
Phase 4
Completed
945 enrolled